Astellas Pharma Inc.CEO(Head Office: Kyoto, Japan; President: Ko Kusumi; hereafter "Kyoto") and Kyoto University Innovation Capital Corporation (Head Office: Kyoto, Japan; President: Ko Kusumi; hereafter "Kyoto") have entered into an agreement to establish a joint venture company, Astellas Pharma Inc.iCAP(hereinafter referred to as "the Company") have concluded a comprehensive strategic collaboration agreement with the aim of promoting social implementation of advanced research results by combining the strengths of the two companies to discover seeds originating from national universities and supporting and fostering entrepreneurship.

Based on this agreement, the two companies will establish a system to regularly exchange information and opinions on drug discovery and healthcare fields. KyotoiCAPis looking forward to working with Astellas Pharma, which has drug discovery capabilities, to promote activities to support the startup and growth of promising venture companies. Astellas has a strong network with promising seeds and venture companies originating from Kyoto University and other national universities in KyotoiCAPand increase opportunities for partnerships that incorporate superior external capabilities and bring cutting-edge science to society as quickly as possible.

In recent years, as drug discovery methods and therapeutic modalities have become more diverse, attempts have been made to integrate technologies between different fields, and the promotion of cross-disciplinary activities that are not limited to medicine and pharmacy will lead to the development of the drug discovery and healthcare fields. Kyoto, JapaniCAPAstellas Pharma Inc. has a track record of making a wide range of investments, including interdisciplinary fusion projects and corporate carve-outs, not limited to drug discovery and healthcare fields, but covering all research fields at Kyoto University. Astellas is engaged in open innovation with several domestic and international academia and venture companies,2017In 2006, the Alliance Station was established within Kyoto University as a base for joint research activities,2021counter for years (following a number in the hito-futa-mi counting system)1Kyoto in MayiCAPoperated byKYOTO-iCAP2We have been involved in the Kyoto-originated ecosystem to create partnership opportunities, such as investing in the No. 1 fund.

Through this agreement, the two companies will contribute to the further development of the Kyoto-based ecosystem of venture companies in various fields,Through partnershipsNational University Research Results.We will strengthen the foundation for social implementation as a new drug and new business.

About Astellas Pharma Inc.
Astellas Pharma Inc. is a global70It is a pharmaceutical company with business activities in more than 100 countries. The company is committed to creating innovative medicines for diseases with high unmet medical needs using cutting-edge biology and combinations of modalities/technologies.Focus Area(Approach). In addition, the medical drug (RxBased on the strengths cultivated in the business, we will provide products and services that combine cutting-edge medical technology with the technologies of partners in other fields (e.g., medical devices, medical equipment, and medical equipment).Rx+®We are also taking on the challenge of creating new products (e.g., new drugs). Astellas is at the forefront of the changing healthcare landscape and is committed to transforming scientific advances into value for patients. For more information about Astellas Pharma Inc,this way (direction close to the speaker or towards the speaker)for more information.

Precautions (Astellas Pharma Inc.)
Statements in this press release regarding current plans, expectations, strategies and assumptions and other statements that are not historical facts are forward-looking statements about Astellas' performance and other matters. These statements are based on management's estimates and assumptions in light of the information currently available to it and involve known and unknown risks and uncertainties. A number of factors could cause these forward-looking statements to differ materially from actual results. Such factors include, but are not limited to (i)I）医薬品市場における事業環境の変化および関係法規制の改正、（ii) exchange rate fluctuations, (iii) Delays in new product launches, (iv(i) the possibility of not achieving the expected results in sales activities for new and existing products; (ii) the possibility that the Company may not be able to achieve the expected results in sales activities for new and existing products; (iii) the possibility that the Company may not be able to achieve the expected results in sales activities for new and existing products; andV) the possibility of not being able to continue to produce competitive new drugs, (vi) including, but not limited to, infringement of intellectual property by third parties. In addition, the information contained in this press release regarding pharmaceuticals (including those under development) is not intended as promotional advertising or medical advice.